• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med . Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection

tetano

Editor, Senior Moderator
J Clin Med


. 2021 Jan 17;10(2):E323.
doi: 10.3390/jcm10020323.
Prognostic Implications of Chronic Heart Failure and Utility of NT-proBNP Levels in Heart Failure Patients with SARS-CoV-2 Infection


Laia C Belarte-Tornero[SUP] 1 2 [/SUP], Sandra Valdivielso-Mor?[SUP] 1 [/SUP], Miren Vicente Elcano[SUP] 3 [/SUP], Eduard Sol?-Gonz?lez[SUP] 1 [/SUP], Sonia Ru?z-Bustillo[SUP] 1 4 [/SUP], Alicia Calvo-Fern?ndez[SUP] 1 2 [/SUP], Isaac Subinara[SUP] 5 [/SUP], Paula Cabero[SUP] 2 3 [/SUP], Cristina Soler[SUP] 2 [/SUP], H?ctor Cubero-Gallego[SUP] 2 3 [/SUP], Beatriz Vaquerizo[SUP] 2 3 4 [/SUP], N?ria Farr?[SUP] 1 2 4 [/SUP]



Affiliations

Abstract

Background: The prevalence and prognostic value of chronic heart failure (CHF) in the setting of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has seldom been studied. The aim of this study was to analyze the prevalence and prognosis of CHF in this setting.
Methods: This single-center study included 829 consecutive patients with SARS-CoV-2 infection from February to April 2020. Patients with a previous history of CHF were matched 1:2 for age and sex. We analyze the prognostic value of pre-existing CHF. Prognostic implications of N terminal pro brain natriuretic peptide (NT-proBNP) levels on admission in the CHF cohort were explored.
Results: A total of 129 patients (43 CHF and 86 non-CHF) where finally included. All-cause mortality was higher in CHF patients compared to non-CHF patients (51.2% vs. 29.1%, p = 0.014). CHF was independently associated with 30-day mortality (hazard ratio (HR) 2.3, confidence interval (CI) 95%: 1.26-2.4). Patients with CHF and high-sensitivity troponin T < 14 ng/L showed excellent prognosis. An NT-proBNP level > 2598 pg/mL on admission was associated with higher 30-day mortality in patients with CHF.
Conclusions: All-cause mortality in CHF patients hospitalized due to SARS-CoV-2 infection was 51.2%. CHF was independently associated with all-cause mortality (HR 2.3, CI 95% 1.26-4.2). NT-proBNP levels could be used for stratification risk purposes to guide medical decisions if larger studies confirm this finding.

Keywords: COVID-19; NT-proBNP; SARS-CoV-2; biomarkers; coronavirus; heart failure; prognosis; troponin.
 
Back
Top Bottom